

December 5, 2018

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces Resolution of Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA® in the U.S.

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today the completion of all the written submissions to and confirmation by the U.S. District Court for the District of New Jersey (the “Court”) for, and the resolution as of December 3, 2018 (U.S. Eastern Time) of, the consolidated patent infringement lawsuit (the “Lawsuit”) which was jointly filed with its U.S. subsidiary, Sunovion Pharmaceuticals Inc., before the Court in February 2018 against a total of 16 generic companies for their proprietary atypical antipsychotic agent, LATUDA® (lurasidone HCl), based on U.S. Patent No. 9,815,827 and No. 9,907,794. This is a follow up on the resolution of disputes under the Lawsuit with all the defendants, as announced in a press release dated November 27, 2018.

The impact of resolving the Lawsuit on Sumitomo Dainippon Pharma’s consolidated financial results of the fiscal year ending March 31, 2019 is not expected to be material. We are currently evaluating the potential impact on Sumitomo Dainippon Pharma’s consolidated financial results of the fiscal year ending March 31, 2020 and thereafter.

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management’s assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this press release, due to a number of factors.

Contact:

Public & Investor Relations Group, Corporate Governance
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)